HMDCF
HUTCHMED (China) Limited
Price Chart
Latest Quote
$2.16
+0.00 (+0.00%)
Current Price
| Previous Close | $2.16 |
| Open | $3.81 |
| Day High | $3.81 |
| Day Low | $3.81 |
| Volume | 468 |
Stock Information
| Shares Outstanding | 859.75M |
| Total Debt | $97.89M |
| Cash Equivalents | $1.37B |
| Revenue | $548.51M |
| Net Income | $456.91M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.86B |
| P/E Ratio | 4.08 |
| EPS (TTM) | $0.53 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $599.37M |
| Sales | $548.51M |
| Income | $456.91M |
| Book/sh | $1.44 |
| Cash/sh | $1.59 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 4.81 |
| Current Ratio | 4.96 |
| Debt/Eq | 7.82 |
| EPS Growth TTM | -83.60% |
Returns & Margins
| ROA | -1.62% |
| ROE | 45.25% |
| Gross Margin | 11.64% |
| Operating Margin | -13.16% |
| Profit Margin | 83.30% |
Ownership
| Insider Ownership | 38.80% |
| Institutional Ownership | 23.26% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 3.39 |
| P/B | 1.50 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.16 |
| SMA50 | $2.52 |
| SMA200 | $3.11 |
| RSI | nan |
| Shares Float | 508.44M |
| Volatility | 0.37 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | -23.40% |
| 6 Months | -40.98% |
| YTD | -40.98% |
| Year | -32.61% |
| 3 Years | -25.52% |
| 5 Years | -57.73% |
| 10 Years | -34.03% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $2.16 | 0 |
| 2026-06-22 | $2.16 | 0 |
| 2026-06-18 | $2.16 | 0 |
| 2026-06-17 | $2.16 | 0 |
| 2026-06-16 | $2.16 | 0 |
| 2026-06-15 | $2.16 | 0 |
| 2026-06-12 | $2.16 | 0 |
| 2026-06-11 | $2.16 | 0 |
| 2026-06-10 | $2.16 | 0 |
| 2026-06-09 | $2.16 | 0 |
| 2026-06-08 | $2.16 | 0 |
| 2026-06-05 | $2.16 | 0 |
| 2026-06-04 | $2.16 | 0 |
| 2026-06-03 | $2.16 | 0 |
| 2026-06-02 | $2.16 | 0 |
| 2026-06-01 | $2.16 | 0 |
| 2026-05-29 | $2.16 | 0 |
| 2026-05-28 | $2.16 | 0 |
| 2026-05-27 | $2.16 | 0 |
| 2026-05-26 | $2.16 | 0 |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
đ° Latest News
Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating
Insider Monkey âĸ 2026-06-02T13:58:04Z
HSBC CEO Pitches Hong Kong Clients, Hires More Bankers After Setbacks
Bloomberg âĸ 2026-05-31T23:00:00Z
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference
MarketBeat âĸ 2026-04-29T03:12:47Z
Should You Be Adding HUTCHMED (China) (LON:HCM) To Your Watchlist Today?
Simply Wall St. âĸ 2026-03-31T07:39:06Z
HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ...
GuruFocus.com âĸ 2026-03-12T01:02:00ZHutchmed price target lowered to $21 from $22 at BofA
TipRanks âĸ 2026-03-07T13:16:28Z
HUTCHMED H2 Earnings Call Highlights
MarketBeat âĸ 2026-03-06T02:07:48Z
Paycom Software, Inc. (PAYC): A Bull Case Theory
Insider Monkey âĸ 2026-02-03T00:49:42Z
Private equity firms among HUTCHMED (China) Limited's (LON:HCM) largest stockholders and were hit after last week's 4.8% price drop
Simply Wall St. âĸ 2025-11-23T07:15:40Z
HUTCHMED (China) (LON:HCM) shareholder returns have been respectable, earning 63% in 3 years
Simply Wall St. âĸ 2025-09-19T06:01:11Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $348,884,000 | $384,447,000 | $311,103,000 | $258,234,000 |
| Cost Of Revenue | $348,884,000 | $384,447,000 | $311,103,000 | $258,234,000 |
| Total Revenue | $630,201,000 | $837,999,000 | $426,409,000 | $356,128,000 |
| Operating Revenue | $630,201,000 | $837,999,000 | $426,409,000 | $356,128,000 |
| Expenses | ||||
| Interest Expense | $2,872,000 | $759,000 | $652,000 | $592,000 |
| Total Expenses | $670,811,000 | $816,490,000 | $832,668,000 | $684,127,000 |
| Other Non Operating Income Expenses | $2,039,000 | $-1,482,000 | $-4,954,000 | $342,000 |
| Net Non Operating Interest Income Expense | $37,208,000 | $35,386,000 | $8,947,000 | $1,484,000 |
| Interest Expense Non Operating | $2,872,000 | $759,000 | $652,000 | $592,000 |
| Operating Expense | $321,927,000 | $432,043,000 | $521,565,000 | $425,893,000 |
| Selling And Marketing Expense | $48,617,000 | $53,392,000 | $43,933,000 | $37,827,000 |
| General And Administrative Expense | $64,296,000 | $79,784,000 | $92,173,000 | $89,298,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $37,729,000 | $100,780,000 | $-360,835,000 | $-194,648,000 |
| Net Interest Income | $37,208,000 | $35,386,000 | $8,947,000 | $1,484,000 |
| Interest Income | $40,080,000 | $36,145,000 | $9,599,000 | $2,076,000 |
| Normalized Income | $41,332,000 | $105,675,334 | $-358,736,088 | $-276,219,500 |
| Net Income From Continuing And Discontinued Operation | $37,729,000 | $100,780,000 | $-360,835,000 | $-194,648,000 |
| Net Income Common Stockholders | $37,729,000 | $100,780,000 | $-360,835,000 | $-194,648,000 |
| Net Income | $37,729,000 | $100,780,000 | $-360,835,000 | $-194,648,000 |
| Net Income Including Noncontrolling Interests | $38,170,000 | $101,094,000 | $-360,386,000 | $-167,041,000 |
| Net Income Continuous Operations | $38,170,000 | $101,094,000 | $-360,386,000 | $-167,041,000 |
| Pretax Income | $-1,107,000 | $58,308,000 | $-410,422,000 | $-215,740,000 |
| Special Income Charges | $-4,804,000 | $-5,766,000 | $0 | $121,310,000 |
| Interest Income Non Operating | $40,080,000 | $36,145,000 | $9,599,000 | $2,076,000 |
| Operating Income | $-40,610,000 | $21,509,000 | $-406,259,000 | $-327,999,000 |
| Gross Profit | $281,317,000 | $453,552,000 | $115,306,000 | $97,894,000 |
| Per Share | ||||
| Diluted EPS | $0.04 | $0.12 | $-0.43 | $-0.25 |
| Basic EPS | $0.04 | $0.12 | $-0.43 | $-0.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,201,000 | $-870,666 | $-353,088 | $27,190,500 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $18,910,000 | $73,040,000 | $-398,654,000 | $-316,720,000 |
| Total Unusual Items | $-4,804,000 | $-5,766,000 | $-2,452,000 | $108,762,000 |
| Total Unusual Items Excluding Goodwill | $-4,804,000 | $-5,766,000 | $-2,452,000 | $108,762,000 |
| Reconciled Depreciation | $12,341,000 | $8,207,000 | $8,664,000 | $7,190,000 |
| EBITDA (Bullshit earnings) | $14,106,000 | $67,274,000 | $-401,106,000 | $-207,958,000 |
| EBIT | $1,765,000 | $59,067,000 | $-409,770,000 | $-215,148,000 |
| Diluted Average Shares | $872,829,129 | $869,196,348 | $847,143,540 | $792,684,524 |
| Basic Average Shares | $855,351,683 | $849,654,296 | $847,143,540 | $792,684,524 |
| Diluted NI Availto Com Stockholders | $37,729,000 | $100,780,000 | $-360,835,000 | $-194,648,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Minority Interests | $-441,000 | $-314,000 | $-449,000 | $-27,607,000 |
| Tax Provision | $7,192,000 | $4,509,000 | $-283,000 | $11,918,000 |
| Impairment Of Capital Assets | $4,804,000 | $5,766,000 | $0 | $0 |
| Research And Development | $212,109,000 | $302,001,000 | $386,893,000 | $299,086,000 |
| Selling General And Administration | $112,913,000 | $133,176,000 | $136,106,000 | $127,125,000 |
| Other Special Charges | - | - | - | $-121,310,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $759,929,000 | $730,541,000 | $610,367,000 | $986,893,000 |
| Total Assets | $1,274,196,000 | $1,279,773,000 | $1,029,445,000 | $1,372,661,000 |
| Total Non Current Assets | $207,641,000 | $182,934,000 | $189,557,000 | $160,585,000 |
| Other Non Current Assets | $15,433,000 | $14,675,000 | $15,745,000 | $21,551,000 |
| Non Current Deferred Taxes Assets | $12,448,000 | $15,456,000 | $15,366,000 | $9,401,000 |
| Investmentin Financial Assets | $5,000,000 | $0 | - | - |
| Current Assets | $1,066,555,000 | $1,096,839,000 | $839,888,000 | $1,212,076,000 |
| Prepaid Assets | $9,005,000 | $8,173,000 | $23,543,000 | $15,383,000 |
| Inventory | $50,400,000 | $50,258,000 | $56,690,000 | $35,755,000 |
| Other Receivables | $12,206,000 | $33,012,000 | $29,180,000 | $49,042,000 |
| Taxes Receivable | $3,297,000 | $2,166,000 | $1,491,000 | $16,616,000 |
| Accounts Receivable | $155,537,000 | $116,894,000 | $97,988,000 | $83,580,000 |
| Allowance For Doubtful Accounts Receivable | $-70,000 | $-171,000 | $-60,000 | $-20,000 |
| Gross Accounts Receivable | $155,607,000 | $117,065,000 | $98,048,000 | $83,600,000 |
| Cash Cash Equivalents And Short Term Investments | $836,110,000 | $886,336,000 | $630,996,000 | $1,011,700,000 |
| Cash And Cash Equivalents | $153,958,000 | $283,589,000 | $313,278,000 | $377,542,000 |
| Cash Equivalents | $69,478,000 | $153,621,000 | $134,952,000 | $272,922,000 |
| Cash Financial | $84,480,000 | $129,968,000 | $178,326,000 | $104,620,000 |
| Non Current Prepaid Assets | - | - | - | $2,387,000 |
| Financial Assets | - | - | - | $2,452,000 |
| Goodwill And Other Intangible Assets | - | - | - | $3,543,000 |
| Other Intangible Assets | - | - | - | $163,000 |
| Debt | ||||
| Total Debt | $89,820,000 | $86,131,000 | $27,008,000 | $34,066,000 |
| Long Term Debt And Capital Lease Obligation | $63,523,000 | $51,049,000 | $23,300,000 | $7,161,000 |
| Long Term Debt | $59,434,000 | $48,189,000 | $18,104,000 | $0 |
| Current Debt And Capital Lease Obligation | $26,297,000 | $35,082,000 | $3,708,000 | $26,905,000 |
| Current Debt | $23,372,000 | $31,155,000 | $0 | $26,905,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $502,343,000 | $536,386,000 | $392,575,000 | $333,147,000 |
| Total Non Current Liabilities Net Minority Interest | $125,781,000 | $133,359,000 | $38,672,000 | $21,489,000 |
| Other Non Current Liabilities | $10,836,000 | $11,346,000 | $12,472,000 | $11,563,000 |
| Non Current Deferred Taxes Liabilities | $2,990,000 | $1,484,000 | $2,710,000 | $2,765,000 |
| Current Liabilities | $376,562,000 | $403,027,000 | $353,903,000 | $311,658,000 |
| Other Current Liabilities | $5,663,000 | $1,896,000 | $17,055,000 | $17,191,000 |
| Payables | $60,189,000 | $53,109,000 | $90,154,000 | $73,737,000 |
| Other Payable | $16,119,000 | $14,202,000 | $17,927,000 | $17,014,000 |
| Total Tax Payable | $1,549,000 | $2,580,000 | $1,112,000 | $15,546,000 |
| Accounts Payable | $42,521,000 | $36,327,000 | $71,115,000 | $41,177,000 |
| Equity | ||||
| Common Stock Equity | $759,929,000 | $730,541,000 | $610,367,000 | $986,893,000 |
| Total Equity Gross Minority Interest | $771,853,000 | $743,387,000 | $636,870,000 | $1,039,514,000 |
| Stockholders Equity | $759,929,000 | $730,541,000 | $610,367,000 | $986,893,000 |
| Retained Earnings | $-833,172,000 | $-870,869,000 | $-971,481,000 | $-610,328,000 |
| Long Term Equity Investment | $77,765,000 | $48,411,000 | $73,777,000 | $76,479,000 |
| Investments In Other Ventures Under Equity Method | - | $0 | $316,000 | $480,000 |
| Other | ||||
| Treasury Shares Number | $16,717,458 | $17,612,685 | $19,601,375 | $8,139,175 |
| Ordinary Shares Number | $854,883,637 | $853,643,585 | $845,173,965 | $856,391,675 |
| Share Issued | $871,601,095 | $871,256,270 | $864,775,340 | $864,530,850 |
| Tangible Book Value | $759,929,000 | $730,541,000 | $610,367,000 | $986,893,000 |
| Invested Capital | $842,735,000 | $809,885,000 | $628,471,000 | $1,013,798,000 |
| Working Capital | $689,993,000 | $693,812,000 | $485,985,000 | $900,418,000 |
| Capital Lease Obligations | $7,014,000 | $6,787,000 | $8,904,000 | $7,161,000 |
| Total Capitalization | $819,363,000 | $778,730,000 | $628,471,000 | $986,893,000 |
| Minority Interest | $11,924,000 | $12,846,000 | $26,503,000 | $52,621,000 |
| Additional Paid In Capital | $1,517,526,000 | $1,522,447,000 | $1,497,273,000 | $1,505,196,000 |
| Capital Stock | $87,160,000 | $87,126,000 | $86,478,000 | $86,453,000 |
| Common Stock | $87,160,000 | $87,126,000 | $86,478,000 | $86,453,000 |
| Non Current Deferred Revenue | $48,432,000 | $69,480,000 | $190,000 | - |
| Long Term Capital Lease Obligation | $4,089,000 | $2,860,000 | $5,196,000 | $7,161,000 |
| Current Capital Lease Obligation | $2,925,000 | $3,927,000 | $3,708,000 | - |
| Available For Sale Securities | $5,000,000 | - | - | - |
| Investmentsin Joint Venturesat Cost | $77,765,000 | $48,411,000 | $73,461,000 | $75,999,000 |
| Net PPE | $96,995,000 | $104,392,000 | $84,669,000 | $53,154,000 |
| Accumulated Depreciation | $-59,317,000 | $-46,569,000 | $-36,864,000 | $-32,899,000 |
| Gross PPE | $156,312,000 | $150,961,000 | $121,533,000 | $86,053,000 |
| Construction In Progress | $7,268,000 | $8,421,000 | $54,550,000 | $19,970,000 |
| Other Properties | $317,000 | $170,000 | $201,000 | $291,000 |
| Machinery Furniture Equipment | $68,046,000 | $63,301,000 | $39,192,000 | $33,944,000 |
| Buildings And Improvements | $80,681,000 | $79,069,000 | $27,590,000 | $31,848,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $26,051,000 | $23,474,000 | $29,298,000 | $19,918,000 |
| Raw Materials | $24,349,000 | $26,784,000 | $27,392,000 | $15,837,000 |
| Other Short Term Investments | $682,152,000 | $602,747,000 | $317,718,000 | $634,158,000 |
| Goodwill | - | - | - | $3,380,000 |
| Land And Improvements | - | - | - | $13,169,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-17,436,000 | $186,646,000 | $-305,263,000 | $-220,979,000 |
| Operating Activities | ||||
| Operating Cash Flow | $497,000 | $219,258,000 | $-268,599,000 | $-204,223,000 |
| Investing Activities | ||||
| Capital Expenditure | $-17,933,000 | $-32,612,000 | $-36,664,000 | $-16,756,000 |
| Investing Cash Flow | $-96,060,000 | $-291,136,000 | $296,588,000 | $-306,320,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-36,064,000 | $-9,071,000 | $-48,084,000 | $-27,309,000 |
| Issuance Of Capital Stock | $790,000 | $5,094,000 | $174,000 | $717,319,000 |
| Financing Cash Flow | $-30,667,000 | $48,660,000 | $-82,763,000 | $650,028,000 |
| Net Common Stock Issuance | $-35,274,000 | $-3,977,000 | $-47,910,000 | $690,010,000 |
| Common Stock Issuance | $790,000 | $5,094,000 | $174,000 | $717,319,000 |
| Dividends Received Cfi | $0 | $29,495,000 | $16,488,000 | $159,118,000 |
| Dividend Received Cfo | $34,936,000 | $42,308,000 | $43,718,000 | $49,872,000 |
| Net Other Financing Charges | - | - | - | $-579,000 |
| Other | ||||
| Repayment Of Debt | $-30,592,000 | $0 | $-26,923,000 | $-579,000 |
| Issuance Of Debt | $36,199,000 | $61,705,000 | $17,753,000 | $0 |
| End Cash Position | $153,958,000 | $283,589,000 | $313,278,000 | $377,542,000 |
| Beginning Cash Position | $283,589,000 | $313,278,000 | $377,542,000 | $235,630,000 |
| Effect Of Exchange Rate Changes | $-3,401,000 | $-6,471,000 | $-9,490,000 | $2,427,000 |
| Changes In Cash | $-126,230,000 | $-23,218,000 | $-54,774,000 | $139,485,000 |
| Common Stock Payments | $-36,064,000 | $-9,071,000 | $-48,084,000 | $-27,309,000 |
| Net Issuance Payments Of Debt | $5,607,000 | $61,705,000 | $-9,170,000 | $-579,000 |
| Net Long Term Debt Issuance | $5,607,000 | $61,705,000 | $-9,170,000 | $-579,000 |
| Long Term Debt Payments | $-30,592,000 | $0 | $-26,923,000 | $-579,000 |
| Long Term Debt Issuance | $36,199,000 | $61,705,000 | $17,753,000 | $0 |
| Net Investment Purchase And Sale | $-79,405,000 | $-285,029,000 | $316,440,000 | $-449,612,000 |
| Sale Of Investment | $1,769,403,000 | $1,342,846,000 | $1,518,453,000 | $921,364,000 |
| Purchase Of Investment | $-1,848,808,000 | $-1,627,875,000 | $-1,202,013,000 | $-1,370,976,000 |
| Net Business Purchase And Sale | $0 | $-2,990,000 | $324,000 | $0 |
| Sale Of Business | $0 | $5,103,000 | $324,000 | $0 |
| Purchase Of Business | $0 | $-8,093,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-16,655,000 | $-32,612,000 | $-36,664,000 | $-15,826,000 |
| Sale Of PPE | $1,278,000 | $0 | $0 | $930,000 |
| Purchase Of PPE | $-17,933,000 | $-32,612,000 | $-36,664,000 | $-16,756,000 |
| Change In Working Capital | $-62,169,000 | $71,146,000 | $58,704,000 | $32,458,000 |
| Change In Other Current Liabilities | $-1,077,000 | $-3,161,000 | $-915,000 | $3,079,000 |
| Change In Other Current Assets | $-27,374,000 | $120,174,000 | $644,000 | $10,984,000 |
| Change In Payable | $8,627,000 | $-36,951,000 | $82,567,000 | $75,789,000 |
| Change In Inventory | $-772,000 | $4,135,000 | $-21,213,000 | $-16,002,000 |
| Change In Receivables | $-41,573,000 | $-13,051,000 | $-2,379,000 | $-41,392,000 |
| Other Non Cash Items | $-4,949,000 | $3,692,000 | $2,739,000 | $-3,683,000 |
| Stock Based Compensation | $21,609,000 | $36,600,000 | $30,586,000 | $41,990,000 |
| Provisionand Write Offof Assets | $547,000 | $677,000 | $336,000 | $-99,000 |
| Deferred Tax | $3,605,000 | $780,000 | $-19,174,000 | $6,904,000 |
| Depreciation And Amortization | $12,341,000 | $8,207,000 | $8,664,000 | $7,190,000 |
| Depreciation | $12,341,000 | $8,207,000 | $8,664,000 | $7,190,000 |
| Net Foreign Currency Exchange Gain Loss | $-49,000 | $-1,574,000 | $13,274,000 | $-2,505,000 |
| Gain Loss On Sale Of PPE | $10,000 | $86,000 | $111,000 | $70,000 |
| Gain Loss On Sale Of Business | $0 | $-141,000 | $0 | $-121,310,000 |
| Net Income From Continuing Operations | $38,170,000 | $101,094,000 | $-360,386,000 | $-167,041,000 |
| Gain Loss On Investment Securities | - | - | $2,452,000 | $12,548,000 |
Fetched: 2026-02-02